SCHEDULE: Vanguard Group Reports Zero Moderna Stake Post-Realignment

The Vanguard Group has reported zero beneficial ownership in Moderna Inc. common stock following an internal realignment effective January 12, 2026.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 6 to Schedule 13G for Moderna Inc. common stock.
• As of the event date March 13, 2026, The Vanguard Group reported 0% beneficial ownership of Moderna Inc. common stock.
• This change is due to an internal realignment on January 12, 2026, where certain subsidiaries and business divisions will now report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has beneficial ownership over securities held by these disaggregated entities, in accordance with SEC Release No. 34-39538 (January 12, 1998).
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Moderna Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative in nature, reflecting a change in The Vanguard Group's internal reporting structure rather than a substantive change in investment strategy or a negative outlook on Moderna Inc.

Positives

• The filing clarifies The Vanguard Group's current beneficial ownership status in Moderna Inc. for the parent entity.
• The internal realignment aligns with SEC guidance (Release No. 34-39538) for disaggregated reporting, enhancing transparency.

Negatives

• The Vanguard Group, as the parent reporting entity, no longer holds any direct beneficial ownership in Moderna Inc. common stock.

Future Outlook

The filing indicates a change in reporting structure for The Vanguard Group, with future beneficial ownership of Moderna Inc. common stock to be reported by its subsidiaries or business divisions on a disaggregated basis.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that this filing reflects a common practice among large asset managers like The Vanguard Group to periodically realign internal reporting structures, especially concerning beneficial ownership disclosures. This disaggregation allows for more granular reporting by individual funds or divisions, which can be beneficial for transparency and compliance with regulatory guidelines, such as SEC Release No. 34-39538. It does not imply a change in overall institutional investment strategy towards Moderna Inc. by Vanguard's broader family of funds, but rather a shift in how those holdings are reported by the parent entity.

Comparison to Industry Standards

• This realignment and disaggregated reporting by The Vanguard Group aligns with practices seen in other large asset management firms, such as BlackRock or State Street, which also manage vast portfolios through various subsidiaries and funds.
• The reliance on SEC Release No. 34-39538 (January 12, 1998) is a standard regulatory compliance approach for large institutional investors to manage their reporting obligations for beneficial ownership.
• The reporting of 0% beneficial ownership by the parent entity, while subsidiaries report separately, is a direct consequence of such internal restructuring, similar to how a parent holding company might report its direct stake versus the aggregate holdings of its diverse investment vehicles.

Stakeholder Impact

• Shareholders (Moderna Inc.): No direct impact on Moderna Inc.'s operations or share price is implied by this administrative change in Vanguard's reporting. The aggregate institutional ownership by Vanguard's various funds may remain, but the parent entity's direct reported stake is now zero.
• Investors (Vanguard Funds): The internal realignment clarifies how beneficial ownership is reported, potentially offering more transparency at the subsidiary level for those tracking specific Vanguard funds.

Next Steps

• Subsidiaries or business divisions of The Vanguard Group, Inc. will report their beneficial ownership of Moderna Inc. separately.

Key Dates

Keywords

Moderna Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Investment Adviser, MRA, Institutional Ownership